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ABSTRACT
Multidrug-resistant isolates of a clonal lineage
of Pseudomonas aeruginosa producing the VIM-2
metallo-b-lactamase (MBL), involved in a large
outbreak in an Italian hospital, were compared
with MBL-negative strains that had caused
outbreaks in two French hospitals. Although the
isolates had different carbapenem MICs, the VIM-
2-producing isolates from Italy carried identical,
or very similar, allelic forms of the oprD gene,
harboured a common class 1 integron, belonged
to the same multilocus sequence type (ST111), and
showed macrorestriction profiles that were
related to those of the MBL-negative French
strains. These results support the concept of
independent acquisition of resistance determi-
nants by members of a widespread clonal lineage
of P. aeruginosa.
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Infections caused by Pseudomonas aeruginosa
are often difficult to treat because of the emer-
gence and spread of acquired resistance to
anti-pseudomonal agents. The carbapenem anti-
biotics meropenem and imipenem are among the
drugs of choice for treating P. aeruginosa infec-
tions, but acquired resistance to these drugs is
increasing [1]. Carbapenem resistance in P. aeru-
ginosa can be mediated by several mechanisms,
including overexpression of efflux systems (e.g.,
MexAB–OprM), loss of the OprD porin, and
production of carbapenemase activity, usually a
metallo-b-lactamase (MBL) [2–5]. The first two
mechanisms (typically associated with a moder-
ate increase in carbapenem MICs) are caused by
chromosomal mutations, and their spread is
dependent on the clonal expansion of the mutant
strains. In contrast, carbapenemase activity
(which can be responsible for high MICs) results
from acquisition of carbapenemase-encoding
determinants via horizontal gene transfer. The
contribution of clonal expansion or horizontal
gene transfer to the dissemination of these resis-
tance determinants has not been defined previ-
ously. Pirnay et al. [6] suggested that P. aeruginosa
has an epidemic population structure, and that a
limited number of widespread clones are respon-
sible for human infections, with serotypes O11
and O12 being frequently associated with multi-
drug-resistant epidemic strains. This hypothesis
was further supported by two surveys using
multilocus sequence typing that identified at least
one clonal complex (BG2) that was widespread in
the UK [7] and another (BG11; serotype O11,
producing a VIM MBL) that was recovered in two
Mediterranean countries [8].
In Trieste University Hospital (northeastern
Italy), a large outbreak of carbapenem-resistant
P. aeruginosa has been in progress since the early
2000s. Macrorestriction profiling of chromosomal
DNA using pulsed-field gel electrophoresis has
identified two different clonal lineages, named
cluster A (serotype O11) and cluster B (sero-
type O12), that produce VIM-1 and VIM-2 MBLs,
respectively [9]. Analysis of 30 representative
isolates (recovered in different years and from
different wards) of cluster A (n = 19) and clus-
ter B (n = 11) by western blot analysis [10]
revealed that the OprD porin was expressed only
by the latter isolates. The oprD genes of five
of these isolates (representative of the five sub-lin-
eages detected within the cluster [9]) were further
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investigated by amplification of the entire oprD
coding sequence. The primers used were D-Fw
(5¢-ATGCGACATGCGTCATGCAAT) and D-Rev
(5¢-CGGTACCTACGCCCTTCCTT); PCRs com-
prised 95C for 5 min, followed by 35 cycles of
95C for 45 s, 60C for 45 s and 72C for 90 s, with
a final extension at 72C for 7 min. The resulting
1594-bp amplicons were sequenced (BMR
Genomics, Padova, Italy). The nucleotide
sequence of the oprD gene of the cluster B index
isolate TS-832347 [9] was submitted to the
GenBank ⁄EMBL database and assigned the acces-
sion number AY528673.
The oprD sequences of the five cluster B isolates
were identical, but were different to that of
P aeruginosa PAO1 (90% nucleotide identity).
The deduced amino-acid sequences revealed the
substitution of 12 consecutive residues in loop L7
of the porin, with a totally divergent stretch of ten
amino-acids. The same mutation has been de-
scribed previously by Epp et al. [11] in an epi-
demic strain, named PP2, isolated at the
University Hospital of Besanc¸on (eastern part of
France). Accordingly, the entire oprD gene of the
PP2 isolate was also sequenced, and this revealed
100% nucleotide identity with the oprD gene of
the cluster B Italian isolates. Another non-MBL-
producing P. aeruginosa isolate, PA507, which
caused a nosocomial outbreak at Pau (southern
part of France) [12], was also included in the
study. The oprD gene from PA507 had a sequence
identical to that of PP2 and the cluster B isolates,
with the exception of a five-nucleotide deletion
(nucleotides 56–60), resulting in a frameshift that
caused a premature translational termination
which explained the previously observed loss of
expression of OprD in PA507 [12]. As it is known
that the oprD gene shows high sequence variabil-
ity [6], this finding suggested the possibility of a
common ancestry of these strains, although they
were recovered from distant hospitals with no
clear epidemiological links.
To investigate this hypothesis, the genomic
relatedness among these strains was studied
using three different techniques: randomly
amplified polymorphic DNA analysis, analysis
of the macrorestriction profiles of chromo-
somal DNA by pulsed-field gel electrophoresis,
and ribotyping, each performed as described
previously [13–15]. Three unrelated isolates
(two isolates belonging to cluster A and one
sporadic isolate) were included in the compar-
ison to verify the discriminatory power of the
methods.
PP2 and PA507 were indistinguishable from
the cluster B isolates by randomly amplified
polymorphic DNA analysis (data not shown)
and by ribotyping (Fig. 1). Slight differences were
revealed by pulsed-field gel electrophoresis anal-
ysis of SpeI-digested genomic DNA, but this
variability (<15%) was comparable to that
observed within cluster B isolates (results not
shown).
The relatedness between the two French strains
and the Italian isolates of cluster B was also
supported by the fact that they carried the same
class 1 integron. This was detected by amplifica-
tion using primers 5¢CS and 3¢CS [16] and
subsequent sequencing, which revealed a cassette
array (aacA4, blaPSE-1, aadA2) that was identical to
that of In99, which has been described previously
in some Portuguese isolates of P. aeruginosa (Gen-
Bank accession number DQ219465) [17]. In con-
trast, the unusual integron In71, which carries the
blaVIM2 cassette and has been identified previ-
ously in the Italian isolates [9], was not present in
the French strains.
Taken together, these findings were consistent
with the hypothesis of a common ancestry of the
strains investigated, and suggested that they
Fig. 1. PvuII ribotyping patterns of the Pseudomonas aeru-
ginosa isolates studied. Lanes: 1, reference strain PAO1; 2
and 3, two isolates belonging to cluster A; 4 and 5, two
isolates belonging to cluster B; 6, PP2; 7, PA507; 8,
a sporadic P. aeruginosa isolate; M, Molecular Weight
Marker II (Roche, Mannheim, Germany).
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could belong to one of the clonal complexes
described previously [7,8]. To investigate this
hypothesis, TS-832347, PP2 and PA507 were
further studied by multilocus sequence typing,
according to the protocol described by Curran
et al. [7] and modified by Giske et al. [8]. The three
strains showed the same allelic profile, ST111,
which belongs to the BG4 clonal complex [7]. This
confirmed previous findings that most sero-
type 012 isolates recovered from different Euro-
pean countries belong to this clonal complex [8].
Although clonally related, TS-832347, PP2 and
PA507 had different carbapenem MICs [9,11,12].
Using the agar dilution method according to the
CLSI guidelines [18], the present study confirmed
their markedly different resistance levels: high
(imipenem 128 mg ⁄L, meropenem 32–64 mg ⁄L)
for the cluster B Italian isolates, which produce an
MBL; medium (imipenem 32 mg ⁄L, meropenem
16 mg ⁄L) for PA507, which lacks OprD expres-
sion; and low (imipenem 4 mg ⁄L, meropenem
1 mg ⁄L) for PP2. Other possible resistance mech-
anisms (e.g., upregulation of the MexAB–OprM
efflux system [2,3] or increased expression of
AmpC cephalosporinase [19]) were not investi-
gated, so it was not possible to assess their
potential contribution to the carbapenem resis-
tance of these strains. However, the present data
suggest that both TS-832347 and PA507 are
derived from a PP2-like ancestor by acquisition
of two distinct carbapenem resistance mecha-
nisms under selective pressure.
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